Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil

Soárez, Patrícia Coelho de; Sartori, Ana Marli Christovam; Santos, Andréia Costa; Itria, Alexander; Novaes, Hillegonda Maria Dutilh; Martelli, Celina Maria Turchi

doi:10.1590/s0102-311x2012000200002

Cited by 10 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…), and the amounts used in outpatient, inpatient and transplant cases and in post-transplantation follow-up. 12 Our study has several limitations. Although we analyzed all the patients who received transplants due to ALF and who were being followed up at our center during the period studied, the sample size was small.…”

Section: Discussionmentioning

confidence: 91%

Healthcare resource utilization and costs of outpatient follow-up after liver transplantation in a university hospital in São Paulo, Brazil: cost description study

et al. 2014

Self Cite

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Data on the costs of outpatient follow-up after liver transplantation are scarce in Brazil. The purpose of the present study was to estimate the direct medical costs of the outpatient follow-up after liver transplantation, from the first outpatient visit after transplantation to five years after transplantation. DESIGN AND SETTING: Cost description study conducted in a university hospital in São Paulo, Brazil. METHODS: Cost data were available for 20 adults who underwent liver transplantation due to acute liver failure (ALF) from 2005 to 2009. The data were retrospectively retrieved from medical records and the hospital accounting information system from December 2010 to January 2011. RESULTS: Mean cost per patient/year was R$ 13,569 (US$ 5,824). The first year of follow-up was the most expensive (R$ 32,546 or US$ 13,968), and medication was the main driver of total costs, accounting for 85% of the total costs over the five-year period and 71.9% of the first-year total costs. In the second year after transplantation, the mean total costs were about half of the amount of the first-year costs (R$ 15,165 or US$ 6,509). Medication was the largest contributor to the costs followed by hospitalization, over the fiveyear period. In the fourth year, the costs of diagnostic tests exceeded the hospitalization costs. CONCLUSION: This analysis provides significant insight into the costs of outpatient follow-up after liver transplantation due to ALF and the participation of each cost component in the Brazilian setting. RESUMO

show abstract

Section: Discussionmentioning

confidence: 91%

Healthcare resource utilization and costs of outpatient follow-up after liver transplantation in a university hospital in São Paulo, Brazil: cost description study

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…It should be noted that cost-effectiveness studies need to be conducted using locally available epidemiological data as such data from other settings have low transferability 13 . Although the age-specific incidence of hepatitis A infection had a significant impact on cost-effectiveness finding 12 , we found that many included studies 20 , 21 , 27 , 28 , 31 adopted such data from the US study 54 , 55 , 71 .…”

Section: Discussionmentioning

confidence: 99%

“…The most comprehensive study 12 published in 2018 included four studies from MICs and 27 studies from HICs. Another systematic review included nine studies conducted in MICs, which were published till 2012 13 . The other identified 11 EE studies, were published between 1995 and 2010 14 .…”

mentioning

confidence: 99%

Economic evaluation of hepatitis A vaccines by income level of the country: A systematic review

et al. 2022

View full text Add to dashboard Cite

Background & objectives: Although several reviews of economic evaluation (EE) studies on hepatitis A virus (HAV) vaccine exist, there remains a need to corroborate such data from time to time. This study aimed to systematically review the literature for reports on EE of HAV vaccination by type of population, characteristics of intervention and income level of the country. Methods: PubMed and Scopus were searched to identify relevant studies from inception up to May 2021 using topic-specific key words in various combinaiton. Full EE studies comparing HAV vaccination to no vaccine or immunoglobulin were included. The risk of bias was assessed by using the ECOBIAS checklist. Results: Among the 1984 identified studies, 43 were found eligible. Of these, 27 were from high-income countries (HICs), 15 from middle-income countries (MICs), and one from low income country. Majority of the studies used Markov model and/or decision tree (n=26). Eight studies used a dynamic model. The discount rate, perspective and time horizon varied across the studies. Universal HAV vaccination without screening was cost-effective among children (14/16, 87.5%) and adolescents (1/5, 20%) but not in adults (0/4, 0%). Analysis by the level of income found that universal HAV vaccination among children without screening was cost-effective in 81.8 per cent of the studies conducted in MICs (9/11) as compared to 66.7 per cent in HICs (4/6). About one-third of the studies conducted among children found that screening and HAV vaccination were cost-effective compared to no vaccination. Interpretation & conclusions: The finding of this review suggest that universal vaccination of children without screening was likely to be cost-effective, especially in MICs. Nevertheless, it should be noted that the methodology varied across studies. Several aspects should also be considered in transferring the EE results across jurisdictions.

show abstract

“…Embora continue sendo bastante notificada no Brasil 11 , a hepatite A é uma doença prevenível através da vacina, que é altamente eficaz. A vacina contra a hepatite A apresenta custo-efetividade no Brasil positivo ao se considerar o custo da vacina, a incidência da doença e os custos gastos com os serviços médicos-hospitalares 12 . Desta forma, com a implementação desta vacina no Programa Nacional de Imunização no Brasil no ano de 2014, mesmo ano dos dados do presente estudo, espera-se que a prevalência de vacinados aumente e, em consequência, reduzam-se as notificações de novos casos.…”

Section: Artigo Originalunclassified

Fatores associados à hepatite viral A na Bahia no ano de 2014

et al. 2017

View full text Add to dashboard Cite

show abstract

Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil

Abstract: Abstract

Cited by 10 publications

References 35 publications

Healthcare resource utilization and costs of outpatient follow-up after liver transplantation in a university hospital in São Paulo, Brazil: cost description study

Healthcare resource utilization and costs of outpatient follow-up after liver transplantation in a university hospital in São Paulo, Brazil: cost description study

Economic evaluation of hepatitis A vaccines by income level of the country: A systematic review

Fatores associados à hepatite viral A na Bahia no ano de 2014

Contact Info

Product

Resources

About